Table 3 Top 50 Gene ontology (GO) enrichment results for ROH islands in Sable Island feral horses

1.76E-08

11

73

RIG-I-like receptor signaling pathway

1.11E-07

7

20

Ascorbate and aldarate metabolism

1.11E-07

7

21

Pentose and glucuronate interconversions

2.01E-07

13

164

JAK-STAT signaling pathway

1.72E-06

37

1741

Extracellular region

2.36E-06

7

34

Porphyrin and chlorophyll metabolism

5.06E-06

8

60

Cytosolic DNA-sensing pathway

5.06E-06

8

60

Drug metabolism

5.21E-06

5

12

Type I interferon receptor binding

6.46E-06

6

25

Glucuronosyltransferase activity

6.46E-06

5

13

Positive regulation of peptidyl-serine phosphorylation of STAT protein

6.46E-06

8

65

Steroid hormone biosynthesis

1.12E-05

7

47

Drug metabolism

1.12E-05

8

71

Retinol metabolism

1.19E-05

7

48

Chemical carcinogenesis

1.48E-05

5

16

Natural killer cell activation involved in immune response

1.48E-05

5

16

Regulation of peptidyl-serine phosphorylation of STAT protein

1.56E-05

12

221

Cytokine receptor binding

1.80E-05

13

271

Cytokine-cytokine receptor interaction

2.67E-05

7

56

Metabolism of xenobiotics by cytochrome P450

3.14E-05

5

19

Serine phosphorylation of STAT protein

4.12E-05

11

201

Lymphocyte proliferation

4.35E-05

11

203

Mononuclear cell proliferation

4.93E-05

10

164

Influenza A

8.52E-05

11

219

Leukocyte proliferation

1.83E-04

8

110

Receptor signaling pathway via JAK-STAT

2.02E-04

8

112

Receptor signaling pathway via STAT

2.25E-04

7

80

Bile secretion

4.03E-04

6

57

Autoimmune thyroid disease

5.38E-04

7

92

Regulation of receptor signaling pathway via JAK-STAT

5.60E-04

7

93

Regulation of receptor signaling pathway via STAT

6.95E-04

5

37

Response to exogenous dsRNA

8.41E-04

6

66

B cell proliferation

9.39E-04

8

142

Biosynthesis of cofactors

1.12E-03

6

70

T cell activation involved in immune response

1.13E-03

3

7

Aryl sulfotransferase activity

1.28E-03

5

43

Response to dsRNA

1.45E-03

8

153

Necroptosis

2.05E-03

9

210

Human immunodeficiency virus 1 infection

2.50E-03

5

50

Natural killer cell activation

2.98E-03

8

171

Tuberculosis

3.03E-03

8

172

Defense response to virus

3.95E-03

7

132

UDP-glycosyltransferase activity

4.15E-03

8

181

Chemical carcinogenesis

4.56E-03

8

184

Kaposi sarcoma-associated herpesvirus infection

6.09E-03

6

99

Toll-like receptor signaling pathway

9.71E-03

7

155

Hepatitis C

9.71E-03

8

207

Lipid and atherosclerosis

1.05E-02

7

158

Cytokine activity

1.05E-02

6

111

Natural killer cell mediated cytotoxicity